Crystal Research CEO Jeffrey Kraws Appointed Chairman of the Board, Synthetic Biologics (SYN-NYSE Amex)

Posted by Colleen Koski

May 11, 2012 at 12:25 PM

ANN ARBOR, Mich.May 11, 2012  /PRNewswire/ -- 

Synthetic Biologics, Inc. (SYN-NYSE Amex), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that to improve its corporate governance and strengthen the Board, it has split the roles of Chairman and Chief Executive Officer, and appointed Jeffrey J. Kraws to serve as its independent, non-executive Chairman of the Board. Mr. Kraws has served on the Company's Board of Directors since January 2006, and will continue to serve on the Compensation and Nominations Committees.

Read More

Topics: Crystal Research Associates, Synthetic Biologics

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic